Methotrexate 10 mg tablets Írsko - angličtina - HPRA (Health Products Regulatory Authority)

methotrexate 10 mg tablets

orion corporation - methotrexate - tablet - 10 milligram(s) - other immunosuppressants; methotrexate

Methotrexate 2.5mg tablets Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

methotrexate 2.5mg tablets

orion pharma (uk) ltd - methotrexate - oral tablet - 2.5mg

Methotrexate 10mg tablets Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

methotrexate 10mg tablets

orion pharma (uk) ltd - methotrexate - oral tablet - 10mg

Methotrexate 10mg tablets Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

methotrexate 10mg tablets

de pharmaceuticals - methotrexate - oral tablet - 10mg

BUVIDAL WEEKLY buprenorphine 16 mg/0.32 mL modified release solution for injection Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

buvidal weekly buprenorphine 16 mg/0.32 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 16 mg - injection, solution - excipient ingredients: ethanol absolute; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support.

BUVIDAL WEEKLY buprenorphine 8 mg/0.16 mL modified release solution for injection Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

buvidal weekly buprenorphine 8 mg/0.16 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 8 mg - injection, solution - excipient ingredients: ethanol absolute; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support.

BUVIDAL MONTHLY buprenorphine 160 mg/0.45 mL modified release solution for injection Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

buvidal monthly buprenorphine 160 mg/0.45 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 160 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.

ASPEN FENTANYL fentanyl (as citrate) 500 microgram/10 mL solution for injection Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

aspen fentanyl fentanyl (as citrate) 500 microgram/10 ml solution for injection

aspen pharmacare australia pty ltd - fentanyl citrate, quantity: 785 microgram (equivalent: fentanyl, qty 500 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - short duration analgesia during premedication, induction and maintenance of anaesthesia, and in the immediate postoperative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic premedication for the induction of anaesthesia, and as an adjunct in the maintanance of general and regional anaesthesia.

ASPEN FENTANYL fentanyl (as citrate) 100 microgram/2 mL solution for injection Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

aspen fentanyl fentanyl (as citrate) 100 microgram/2 ml solution for injection

aspen pharmacare australia pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - short duration analgesia during premedication, induction and maintenance of anaesthesia, and in the immediate postoperative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic premedication for the induction of anaesthesia, and as an adjunct in the maintanance of general and regional anaesthesia.

MORPHINE SULFATE 30 mg/1 mL MEDSURGE morphine sulfate pentahydrate 30 mg/1 mL solution for injection ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

morphine sulfate 30 mg/1 ml medsurge morphine sulfate pentahydrate 30 mg/1 ml solution for injection ampoule

medsurge pharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.